Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Monte Rosa Therapeutics, Inc. (GLUE) had Free Cash Flow per Share of $-1.02 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$23.19M |
|
$-12.29M |
|
-- |
|
$23.19M |
|
$38.75M |
|
$-15.55M |
|
$4.46M |
|
$-11.10M |
|
$-11.10M |
|
$-12.29M |
|
$-12.29M |
|
$-12.29M |
|
$-12.29M |
|
$-15.55M |
|
$-13.43M |
|
82.19M |
|
82.19M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$299.46M |
|
$29.05M |
|
$60.12M |
|
$359.59M |
|
$41.85M |
|
-- |
|
$49.65M |
|
$91.51M |
|
$268.08M |
|
$268.08M |
|
$268.08M |
|
61.72M |
|
| Cash Flow Statement Financials | |
$-80.21M |
|
$-74.91M |
|
$0.38M |
|
$229.12M |
|
$74.38M |
|
$-154.74M |
|
$10.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-67.06% |
|
-67.06% |
|
-- |
|
-47.84% |
|
-53.01% |
|
$-83.49M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
9.79 |
|
9.20 |
|
-4.59% |
|
-4.59% |
|
-3.42% |
|
-4.59% |
|
$4.34 |
|
|
Free Cash Flow per Share |
$-1.02 |
$-0.98 |
|